1

RPR File No.: EX95001-US

N THE ONITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

Perricaudet et al.

Group Art Unit: 1633

Serial No.

08/894,246

Examiner: S. Chen

International Filing Date:

February 12, 1996

For:

Medicinal Combination Useful For In Vivo Exogenic Transfection And

Expression

To:

Assistant Commissioner for Patents

Washington, D.C. 20231

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the: Assistant Commissioner for Patents, Washington, D.C. 20231.

Paula L. Dickey

(Type or print name of person mailing paper

Date: Occarber 8, 999

(Signature of person mailing paper)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR §§ 1.97 AND 1.98

Dear Sir:

Applicant submits herewith a list of patents and publications PD and PE, and copies thereof, as required by 37 C.F.R. § 1.98, which Applicant believes the Examiner may consider to be material to the patentability of claims of this application and for which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicant has previously filed an Information Disclosure Statement for this application on September 9, 1997.

While the patents and publications disclosed herein may be "material" within the meaning of 37 CFR § 1.56, Applicant's inclusion thereof in this Information Disclosure Statement is not intended to constitute an admission that any such patent or publication is "prior art" for this invention unless specifically designated as such.

RPR File No.: EX95001-US

In accordance with 37 CFR § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that the information cited is material to patentability as defined in 37 CFR § 1.56(b).

Applicant believes that the claims in the present application are patentably distinguishable over the patents and publications listed on the attached Information Disclosure Citation Form.

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits but before the mailing date of a final action under 37 C.F.R. § 1.113 or a notice of allowance under 37 C.F.R. § 1.311. The Commissioner is hereby authorized to deduct the fee of \$240.00 for submission of this Information Disclosure Statement, pursuant to 37 C.F.R. §§ 1.97 (c) and 1.17 (p), from Deposit Account No. 18-1982. The Commissioner is hereby authorized also to deduct any underpayment from, or credit any overpayment further to the filing of this Information Disclosure Statement to said Deposit Account. An original and one copy of this Statement are enclosed.

Respectfully submitted,

Dated: December 7, 1999

Rhône-Poulenc Rorer Inc. Mailstop #3C43 P.O. Box 5093

Collegeville, PA 19426-0997 Telephone: (610) 454-3178 Facsimile: (610) 454-3808 Ŕachel H. Rondinelli, Ph.D.

Agent for Applicant Registration No: 45,052